Could the immune checkpoint inhibitor against colorectal cancer in constitutional mismatch repair deficiency syndrome prevent new cancer formation?

Pediatr Blood Cancer. 2022 Jan;69(1):e29312. doi: 10.1002/pbc.29312. Epub 2021 Aug 28.

Authors

Affiliations

¹ Department of Pediatric Hematology and Oncology, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
² Department of Diagnostic Pathology, Osaka City General Hospital, Osaka, Japan.
³ Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan.
⁴ Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan.
⁵ Cancer Treatment Center, Toyonaka Municipal Hospital, Osaka, Japan.

PMID: 34453473
DOI: 10.1002/pbc.29312

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Brain Neoplasms*
Child
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / surgery
DNA Mismatch Repair
Female
Humans
Immune Checkpoint Inhibitors*
Neoplasm Recurrence, Local / prevention & control
Neoplastic Syndromes, Hereditary*

Substances

Immune Checkpoint Inhibitors

Supplementary concepts

Turcot syndrome